Ranbaxy beats US Lipitor antitrust suit on appeal
MLex Summary: Plaintiffs bringing US antitrust claims against Ranbaxy over the drug Lipitor lack antitrust standing, and thus are inadequate class representatives, according to an appeals court. The Court of Appeals...To view the full article, register now.
Already a subscriber? Click here to view full article